N90

1-(diphenylmethyl)-4-[(2E)-3-phenylprop-2-en-1-yl]piperazine


Toggle HydrogenToggle Labels

Chemical Component Summary

Name1-(diphenylmethyl)-4-[(2E)-3-phenylprop-2-en-1-yl]piperazine
SynonymsCinnarizine
Identifiers1-(diphenylmethyl)-4-[(~{E})-3-phenylprop-2-enyl]piperazine
FormulaC26 H28 N2
Molecular Weight368.514
TypeNON-POLYMER
Isomeric SMILESc1ccc(cc1)/C=C/CN2CCN(CC2)C(c3ccccc3)c4ccccc4
InChIInChI=1S/C26H28N2/c1-4-11-23(12-5-1)13-10-18-27-19-21-28(22-20-27)26(24-14-6-2-7-15-24)25-16-8-3-9-17-25/h1-17,26H,18-22H2/b13-10+
InChIKeyDERZBLKQOCDDDZ-JLHYYAGUSA-N

Chemical Details

Formal Charge0
Atom Count56
Chiral Atom Count0
Bond Count59
Aromatic Bond Count18

Drug Info: DrugBank

DrugBank IDDB00568 
NameCinnarizine
Groups
  • investigational
  • approved
DescriptionFirst synthesized by Janssen Pharmaceuticals in 1955, cinnarizine is an anti-histaminic drug mainly used for the control of vestibular disorders and motion sickness. Cinnarizine is a specific calcium channel blocker that primarily works on the central vestibular system to interfere with the signal transmission between vestibular apparatus of the inner ear and the vomiting centre of the hypothalamus. Cinnarizine could be also viewed as a nootropic drug because of its vasorelaxating abilities (due to calcium channel blockage), which happen mostly in brain. Combination use of cinnarizine with other nootropics, such as [piracetam] resulted in enhanced effect of boosting brain oxygen supply.
Synonyms
  • 1-Benzhydryl-4-cinnamylpiperazin
  • 1-(Diphenylmethyl)-4-(3-phenyl-2-propenyl)piperazine
  • Cinarizina
  • 1-Cinnamyl-4-(diphenylmethyl)piperazine
  • Cinnarizine hydrochloride
IndicationFor the treatment of vertigo/meniere's disease, nausea and vomiting, motion sickness and also useful for vestibular symptoms of other origins.
Categories
  • Agents causing hyperkalemia
  • Antiarrhythmic agents
  • Antivertigo Preparations
  • Bradycardia-Causing Agents
  • Calcium Channel Blockers
ATC-Code
  • N07CA52
  • N07CA02
CAS number298-57-7

Drug Targets

NameTarget SequencePharmacological ActionActions
Histamine H1 receptorMSLPNSSCLLEDKMCEGNKTTMASPQLMPLVVVLSTICLVTVGLNLLVLY...unknownantagonist
Voltage-dependent L-type calcium channel subunit alpha-1CMVNENTRMYIPEENHQGSNYGSPRPAHANMNANAAAGLAPEHIPTPGAAL...unknowninhibitor
Voltage-dependent L-type calcium channel subunit alpha-1DMMMMMMMKKMQHQRQQQADHANEANYARGTRLPLSGEGPTSQPNSSKQTV...unknowninhibitor
Voltage-dependent L-type calcium channel subunit alpha-1FMSESEGGKDTTPEPSPANGAGPGPEWGLCPGPPAVEGESSGASGLGTPKR...unknowninhibitor
Voltage-dependent L-type calcium channel subunit alpha-1SMEPSSPQDEGLRKKQPKKPVPEILPRPPRALFCLTLENPLRKACISIVEW...unknowninhibitor
View More
Drug Info/Drug Targets: DrugBank 3.0: a comprehensive resource for 'omics' research on drugs. Knox C, Law V, Jewison T, Liu P, Ly S, Frolkis A, Pon A, Banco K, Mak C, Neveu V, Djoumbou Y, Eisner R, Guo AC, Wishart DS. Nucleic Acids Res. 2011 Jan; 39 (Database issue):D1035-41. | PMID:21059682

Related Resource References

Resource NameReference
Pharos CHEMBL43064
PubChem 1547484
ChEMBL CHEMBL43064
ChEBI CHEBI:131176, CHEBI:31403
CCDC/CSD CINNAZ